市場調査レポート

商品コード

1360319

細胞および遺伝子治療製造市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Cell and Gene Therapy Manufacturing Market (Therapy Type: Cell Therapy and Gene Therapy; Product Type: Consumables, Equipment, and Software) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日: 2023年08月24日 | 発行: Transparency Market Research

| ページ情報: 英文 284 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 910,626円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,382,046円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,853,466円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

細胞および遺伝子治療製造市場- レポートの範囲

世界の細胞および遺伝子治療製造市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの細胞および遺伝子治療製造の世界市場の収益を掲載しています。また、2023年から2031年までの世界の細胞および遺伝子治療製造市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、細胞および遺伝子治療製造市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書を参照することが含まれていました。

市場スナップショット
2023年の市場価値	11億米ドル
2031年の市場価値	88億米ドル
CAGR	25.2%

このレポートは、世界の細胞および遺伝子治療製造市場の競合情勢を詳しく掘り下げています。世界の細胞および遺伝子治療製造市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の細胞および遺伝子治療製造市場のプレーヤーの属性です。

イントロダクションと定義
主な調査結果/発展
市場金額予測：治療法別、2017-2031
- 細胞治療
  - 同種異系
    - 間葉系幹細胞
    - T細胞
    - 人工多能性幹細胞
    - ナチュラルキラー細胞
    - 造血幹細胞
    - その他
  - 自己由来
    - T細胞
    - 造血幹細胞
    - 間葉系幹細胞
    - ナチュラルキラー細胞
    - その他
- 遺伝子治療
  - ウイルスベクター
    - レンチウイルスベクター
    - アデノ随伴ウイルスベクター
    - 他のウイルスベクター
  - 非ウイルスベクター
    - エレクトロポレーション
    - その他の非ウイルスベクター
市場魅力分析：治療法別

第7章細胞および遺伝子治療製造市場の分析と予測：製品タイプ別

イントロダクションと定義
主な調査結果/発展
市場金額予測：製品タイプ別、2017-2031
- 消耗品
- 装置
  - 細胞処理装置
  - 使い捨て機器
  - その他の設備
- ソフトウェアとシステム
市場魅力分析：製品タイプ別

第8章細胞および遺伝子治療製造市場の分析と予測：テクノロジー別

イントロダクションと定義
主な調査結果/発展
市場金額予測：テクノロジー別、2017-2031
- 細胞培養と増殖
- ウイルスベクターの生産
- 細胞の選別と精製
- 遺伝子編集
- その他
市場魅力分析：テクノロジー別

第9章細胞および遺伝子治療製造市場の分析と予測：適応症別

イントロダクションと定義
主な調査結果/発展
市場金額予測：適応症別、2017-2031
- 腫瘍学疾患
- 循環器疾患
- 整形外科疾患
- 感染症
- その他
市場魅力分析：適応症別

第10章細胞および遺伝子治療製造市場の分析と予測：エンドユーザー別

イントロダクションと定義
主な調査結果/発展
市場金額予測：エンドユーザー別、2017-2031
- 製薬およびバイオテクノロジー企業
- 受託製造組織（CMO）
市場魅力分析：エンドユーザー別

第11章細胞および遺伝子治療製造市場の分析と予測：地域別

主な調査結果
市場金額予測：地域別、2017-2031
- 北米
- 欧州
- アジア太平洋地域
- ラテンアメリカ
- 中東・アフリカ
市場魅力分析：地域別

第12章北米の細胞および遺伝子治療製造市場の分析と予測

第13章欧州の細胞および遺伝子治療製造市場の分析と予測

第14章アジア太平洋の細胞および遺伝子治療製造市場の分析と予測

第15章ラテンアメリカの細胞および遺伝子治療製造市場の分析と予測

第16章中東およびアフリカの細胞および遺伝子治療製造市場の分析と予測

第17章競合情勢

市場プレーヤー-競合マトリックス（企業の階層および規模別）
市場シェア分析：企業別（2022年）
企業プロファイル
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- General Electric Company（GE Healthcare）
- Getinge AB
- Lonza Group Ltd.
- Merck KGaA
- Sartorius AG（Sartorius Stedim Biotech SA）
- Thermo Fisher Scientific Inc.
- MaxCyte
- Fresenius Medical Care AG &Co. KGaA

図表

List of Tables

Table 01: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 02: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 03: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 04: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 05: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 06: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 07: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 08: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 09: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 10: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 11: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 12: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 14: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 15: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 16: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 17: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 18: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 19: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 20: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 21: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 22: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 23: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
Table 24: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 25: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 26: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 27: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 28: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 29: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 30: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 31: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 32: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 33: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 34: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 35: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 36: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
Table 37: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 38: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 39: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 40: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 41: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 42: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 43: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 44: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 45: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 46: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 47: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 48: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 49: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
Table 50: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 51: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 52: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 53: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 54: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 55: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 56: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 57: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 58: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 59: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 60: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 61: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 62: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
Table 63: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 64: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 65: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 66: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 67: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 68: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
Table 69: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
Table 70: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
Table 71: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
Table 72: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
Table 73: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
Table 74: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 75: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
Table 76: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 77: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 78: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

Figure 01: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Cell and Gene Therapy Manufacturing Market Value Share, by Therapy Type, 2022
Figure 03: Global Cell and Gene Therapy Manufacturing Market Value Share, by Product Type, 2022
Figure 04: Global Cell and Gene Therapy Manufacturing Market Value Share, by Indication, 2022
Figure 05: Global Cell and Gene Therapy Manufacturing Market Value Share, by Technology, 2022
Figure 06: Global Cell and Gene Therapy Manufacturing Market Value Share, by End-user, 2022
Figure 07: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 08: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 09: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Cell Therapy, 2017-2031
Figure 10: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Gene Therapy, 2017-2031
Figure 11: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 12: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 13: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Consumables, 2017-2031
Figure 14: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Viral Vector Production, 2017-2031
Figure 15: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
Figure 16: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 17: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 18: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Cell Culture & Expansion, 2017-2031
Figure 19: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Viral Vector Production, 2017-2031
Figure 20: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Irreversible Cell Sorting & Purification, 2017-2031
Figure 21: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Gene Editing, 2017-2031
Figure 22: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
Figure 23: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 24: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 25: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Oncology, 2017-2031
Figure 26: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017-2031
Figure 27: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Orthopedic Disease, 2017-2031
Figure 28: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Infectious Disease, 2017-2031
Figure 29: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
Figure 30: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 31: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 32: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
Figure 33: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Contract Manufacturing Organizations (CMOs), 2017-2031
Figure 34: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Region, 2022 and 2031
Figure 35: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Region, 2023-2031
Figure 36: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country, 2022 and 2031
Figure 38: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country, 2023-2031
Figure 39: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 40: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 41: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 42: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 43: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 44: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 45: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 46: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 47: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 48: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 49: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 52: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 53: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 54: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 55: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 56: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 57: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 58: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 59: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 60: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 61: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 62: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 63: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 64: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 65: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 66: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 67: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 68: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 69: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 70: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 71: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 72: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 73: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 74: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 75: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 76: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 77: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 78: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 79: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 80: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 81: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 82: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 83: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 84: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 85: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 86: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 87: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 88: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
Figure 89: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 90: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 91: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
Figure 92: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 93: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 94: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 95: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 96: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
Figure 97: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
Figure 98: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
Figure 99: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 100: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031

Product Code: TMRGL85808

Cell and Gene Therapy Manufacturing Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing market.

Market Snapshot
Market Value in 2023	US$ 1.1 Bn
Market Value in 2031	US$ 8.8 Bn
CAGR	25.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing market. Key players operating in the global cell and gene therapy manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Market Report:

What is the sales/revenue generated by cell and gene therapy manufacturing across all regions during the forecast period?
What are the opportunities in the global cell and gene therapy manufacturing market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Cell and Gene Therapy Manufacturing Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Technological Advancements
5.2. Reimbursement Scenario by Region/Globally
5.3. Regulatory Scenario by Region/globally
5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2017-2031
- 6.3.1. Cell Therapy
  - 6.3.1.1. Allogeneic
    - 6.3.1.1.1. Mesenchymal Stem Cells
    - 6.3.1.1.2. T-cells
    - 6.3.1.1.3. Induced Pluripotent Stem Cells
    - 6.3.1.1.4. Natural Killer Cells
    - 6.3.1.1.5. Hematopoietic Stem Cells
    - 6.3.1.1.6. Others
  - 6.3.1.2. Autologous
    - 6.3.1.2.1. T-cells
    - 6.3.1.2.2. Hematopoietic Stem Cells
    - 6.3.1.2.3. Mesenchymal Stem Cells
    - 6.3.1.2.4. Natural Killer Cells
    - 6.3.1.2.5. Others
- 6.3.2. Gene Therapy
  - 6.3.2.1. Viral Vector
    - 6.3.2.1.1. Lentiviral Vector
    - 6.3.2.1.2. Adeno-associated Virus Vectors
    - 6.3.2.1.3. Other Viral Vectors
  - 6.3.2.2. Non-viral Vector
    - 6.3.2.2.1. Electroporation
    - 6.3.2.2.2. Other Non-viral Vectors
6.4. Market Attractiveness Analysis, by Therapy Type

7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Product Type, 2017-2031
- 7.3.1. Consumables
- 7.3.2. Equipment
  - 7.3.2.1. Cell Processing Equipment
  - 7.3.2.2. Single-use Equipment
  - 7.3.2.3. Other Equipment
- 7.3.3. Software & Systems
7.4. Market Attractiveness Analysis, by Product Type

8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technology, 2017-2031
- 8.3.1. Cell Culture & Expansion
- 8.3.2. Viral Vector Production
- 8.3.3. Cell Sorting & Purification
- 8.3.4. Gene Editing
- 8.3.5. Others
8.4. Market Attractiveness Analysis, by Technology

9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication

9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
- 9.3.1. Oncology Disease
- 9.3.2. Cardiovascular Disease
- 9.3.3. Orthopedic Disease
- 9.3.4. Infectious Disease
- 9.3.5. Others
9.4. Market Attractiveness Analysis, by Indication

10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user

10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017-2031
- 10.3.1. Pharmaceutical & Biotechnology Companies
- 10.3.2. Contract Manufacturing Organizations (CMOs)
10.4. Market Attractiveness Analysis, by End-user

11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region

11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region

12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017-2031
- 12.2.1. Cell Therapy
  - 12.2.1.1. Allogeneic
    - 12.2.1.1.1. Mesenchymal Stem Cells
    - 12.2.1.1.2. T-cells
    - 12.2.1.1.3. Induced Pluripotent Stem Cells
    - 12.2.1.1.4. Natural Killer Cells
    - 12.2.1.1.5. Hematopoietic Stem Cells
    - 12.2.1.1.6. Others
  - 12.2.1.2. Autologous
    - 12.2.1.2.1. T-cells
    - 12.2.1.2.2. Hematopoietic Stem Cells
    - 12.2.1.2.3. Mesenchymal Stem Cells
    - 12.2.1.2.4. Natural Killer Cells
    - 12.2.1.2.5. Others
- 12.2.2. Gene Therapy
  - 12.2.2.1. Viral Vector
    - 12.2.2.1.1. Lentiviral Vector
    - 12.2.2.1.2. Adeno-associated Virus Vectors
    - 12.2.2.1.3. Other Viral Vectors
  - 12.2.2.2. Non-viral Vector
    - 12.2.2.2.1. Electroporation
    - 12.2.2.2.2. Other Non-viral Vectors
12.3. Market Value Forecast, by Product Type, 2017-2031
- 12.3.1. Consumables
- 12.3.2. Equipment
  - 12.3.2.1. Cell Processing Equipment
  - 12.3.2.2. Single-use Equipment
  - 12.3.2.3. Other Equipment
- 12.3.3. Software & Systems
12.4. Market Value Forecast, by Technology, 2017-2031
- 12.4.1. Cell Culture & Expansion
- 12.4.2. Viral Vector Production
- 12.4.3. Cell Sorting & Purification
- 12.4.4. Gene Editing
- 12.4.5. Others
12.5. Market Value Forecast, by Indication, 2017-2031
- 12.5.1. Oncology Disease
- 12.5.2. Cardiovascular Disease
- 12.5.3. Orthopedic Disease
- 12.5.4. Infectious Disease
- 12.5.5. Others
12.6. Market Value Forecast, by End-user, 2017-2031
- 12.6.1. Pharmaceutical & Biotechnology Companies
- 12.6.2. Contract Manufacturing Organizations (CMOs)
12.7. Market Value Forecast, by Country, 2017-2031
- 12.7.1. U.S.
- 12.7.2. Canada
12.8. Market Attractiveness Analysis
- 12.8.1. By Therapy Type
- 12.8.2. By Product Type
- 12.8.3. By Technology
- 12.8.4. By Indication
- 12.8.5. By End-user
- 12.8.6. By Country

13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017-2031
- 13.2.1. Cell Therapy
  - 13.2.1.1. Allogeneic
    - 13.2.1.1.1. Mesenchymal Stem Cells
    - 13.2.1.1.2. T-cells
    - 13.2.1.1.3. Induced Pluripotent Stem Cells
    - 13.2.1.1.4. Natural Killer Cells
    - 13.2.1.1.5. Hematopoietic Stem Cells
    - 13.2.1.1.6. Others
  - 13.2.1.2. Autologous
    - 13.2.1.2.1. T-cells
    - 13.2.1.2.2. Hematopoietic Stem Cells
    - 13.2.1.2.3. Mesenchymal Stem Cells
    - 13.2.1.2.4. Natural Killer Cells
    - 13.2.1.2.5. Others
- 13.2.2. Gene Therapy
  - 13.2.2.1. Viral Vector
    - 13.2.2.1.1. Lentiviral Vector
    - 13.2.2.1.2. Adeno-associated Virus Vectors
    - 13.2.2.1.3. Other Viral Vectors
  - 13.2.2.2. Non-viral Vector
    - 13.2.2.2.1. Electroporation
    - 13.2.2.2.2. Other Non-viral Vectors
13.3. Market Value Forecast, by Product Type, 2017-2031
- 13.3.1. Consumables
- 13.3.2. Equipment
  - 13.3.2.1. Cell Processing Equipment
  - 13.3.2.2. Single-use Equipment
  - 13.3.2.3. Other Equipment
- 13.3.3. Software & Systems
13.4. Market Value Forecast, by Technology, 2017-2031
- 13.4.1. Cell Culture & Expansion
- 13.4.2. Viral Vector Production
- 13.4.3. Cell Sorting & Purification
- 13.4.4. Gene Editing
- 13.4.5. Others
13.5. Market Value Forecast, by Indication, 2017-2031
- 13.5.1. Oncology Disease
- 13.5.2. Cardiovascular Disease
- 13.5.3. Orthopedic Disease
- 13.5.4. Infectious Disease
- 13.5.5. Others
13.6. Market Value Forecast, by End-user, 2017-2031
- 13.6.1. Pharmaceutical & Biotechnology Companies
- 13.6.2. Contract Manufacturing Organizations (CMOs)
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Italy
- 13.7.5. Spain
- 13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
- 13.8.1. By Therapy Type
- 13.8.2. By Product Type
- 13.8.3. By Technology
- 13.8.4. By Indication
- 13.8.5. By End-user
- 13.8.6. By Country/Sub-region

14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017-2031
- 14.2.1. Cell Therapy
  - 14.2.1.1. Allogeneic
    - 14.2.1.1.1. Mesenchymal Stem Cells
    - 14.2.1.1.2. T-cells
    - 14.2.1.1.3. Induced Pluripotent Stem Cells
    - 14.2.1.1.4. Natural Killer Cells
    - 14.2.1.1.5. Hematopoietic Stem Cells
    - 14.2.1.1.6. Others
  - 14.2.1.2. Autologous
    - 14.2.1.2.1. T-cells
    - 14.2.1.2.2. Hematopoietic Stem Cells
    - 14.2.1.2.3. Mesenchymal Stem Cells
    - 14.2.1.2.4. Natural Killer Cells
    - 14.2.1.2.5. Others
- 14.2.2. Gene Therapy
  - 14.2.2.1. Viral Vector
    - 14.2.2.1.1. Lentiviral Vector
    - 14.2.2.1.2. Adeno-associated Virus Vectors
    - 14.2.2.1.3. Other Viral Vectors
  - 14.2.2.2. Non-viral Vector
    - 14.2.2.2.1. Electroporation
    - 14.2.2.2.2. Other Non-viral Vectors
14.3. Market Value Forecast, by Product Type, 2017-2031
- 14.3.1. Consumables
- 14.3.2. Equipment
  - 14.3.2.1. Cell Processing Equipment
  - 14.3.2.2. Single-use Equipment
  - 14.3.2.3. Other Equipment
- 14.3.3. Software & Systems
14.4. Market Value Forecast, by Technology, 2017-2031
- 14.4.1. Cell Culture & Expansion
- 14.4.2. Viral Vector Production
- 14.4.3. Cell Sorting & Purification
- 14.4.4. Gene Editing
- 14.4.5. Others
14.5. Market Value Forecast, by Indication, 2017-2031
- 14.5.1. Oncology Disease
- 14.5.2. Cardiovascular Disease
- 14.5.3. Orthopedic Disease
- 14.5.4. Infectious Disease
- 14.5.5. Others
14.6. Market Value Forecast, by End-user, 2017-2031
- 14.6.1. Pharmaceutical & Biotechnology Companies
- 14.6.2. Contract Manufacturing Organizations (CMOs)
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
- 14.8.1. By Therapy Type
- 14.8.2. By Product Type
- 14.8.3. By Technology
- 14.8.4. By Indication
- 14.8.5. By End-user
- 14.8.6. By Country/Sub-region

15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2017-2031
- 15.2.1. Cell Therapy
  - 15.2.1.1. Allogeneic
    - 15.2.1.1.1. Mesenchymal Stem Cells
    - 15.2.1.1.2. T-cells
    - 15.2.1.1.3. Induced Pluripotent Stem Cells
    - 15.2.1.1.4. Natural Killer Cells
    - 15.2.1.1.5. Hematopoietic Stem Cells
    - 15.2.1.1.6. Others
  - 15.2.1.2. Autologous
    - 15.2.1.2.1. T-cells
    - 15.2.1.2.2. Hematopoietic Stem Cells
    - 15.2.1.2.3. Mesenchymal Stem Cells
    - 15.2.1.2.4. Natural Killer Cells
    - 15.2.1.2.5. Others
- 15.2.2. Gene Therapy
  - 15.2.2.1. Viral Vector
    - 15.2.2.1.1. Lentiviral Vector
    - 15.2.2.1.2. Adeno-associated Virus Vectors
    - 15.2.2.1.3. Other Viral Vectors
  - 15.2.2.2. Non-viral Vector
    - 15.2.2.2.1. Electroporation
    - 15.2.2.2.2. Other Non-viral Vectors
15.3. Market Value Forecast, by Product Type, 2017-2031
- 15.3.1. Consumables
- 15.3.2. Equipment
  - 15.3.2.1. Cell Processing Equipment
  - 15.3.2.2. Single-use Equipment
  - 15.3.2.3. Other Equipment
- 15.3.3. Software & Systems
15.4. Market Value Forecast, by Technology, 2017-2031
- 15.4.1. Cell Culture & Expansion
- 15.4.2. Viral Vector Production
- 15.4.3. Cell Sorting & Purification
- 15.4.4. Gene Editing
- 15.4.5. Others
15.5. Market Value Forecast, by Indication, 2017-2031
- 15.5.1. Oncology Disease
- 15.5.2. Cardiovascular Disease
- 15.5.3. Orthopedic Disease
- 15.5.4. Infectious Disease
- 15.5.5. Others
15.6. Market Value Forecast, by End-user, 2017-2031
- 15.6.1. Pharmaceutical & Biotechnology Companies
- 15.6.2. Contract Manufacturing Organizations (CMOs)
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
- 15.8.1. By Therapy Type
- 15.8.2. By Product Type
- 15.8.3. By Technology
- 15.8.4. By Indication
- 15.8.5. By End-user
- 15.8.6. By Country/Sub-region

16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast

16.1. Introduction
- 16.1.1. Key Findings
16.2. Market Value Forecast, by Therapy Type, 2017-2031
- 16.2.1. Cell Therapy
  - 16.2.1.1. Allogeneic
    - 16.2.1.1.1. Mesenchymal Stem Cells
    - 16.2.1.1.2. T-cells
    - 16.2.1.1.3. Induced Pluripotent Stem Cells
    - 16.2.1.1.4. Natural Killer Cells
    - 16.2.1.1.5. Hematopoietic Stem Cells
    - 16.2.1.1.6. Others
  - 16.2.1.2. Autologous
    - 16.2.1.2.1. T-cells
    - 16.2.1.2.2. Hematopoietic Stem Cells
    - 16.2.1.2.3. Mesenchymal Stem Cells
    - 16.2.1.2.4. Natural Killer Cells
    - 16.2.1.2.5. Others
- 16.2.2. Gene Therapy
  - 16.2.2.1. Viral Vector
    - 16.2.2.1.1. Lentiviral Vector
    - 16.2.2.1.2. Adeno-associated Virus Vectors
    - 16.2.2.1.3. Other Viral Vectors
  - 16.2.2.2. Non-viral Vector
    - 16.2.2.2.1. Electroporation
    - 16.2.2.2.2. Other Non-viral Vectors
16.3. Market Value Forecast, by Product Type, 2017-2031
- 16.3.1. Consumables
- 16.3.2. Equipment
  - 16.3.2.1. Cell Processing Equipment
  - 16.3.2.2. Single-use Equipment
  - 16.3.2.3. Other Equipment
- 16.3.3. Software & Systems
16.4. Market Value Forecast, by Technology, 2017-2031
- 16.4.1. Cell Culture & Expansion
- 16.4.2. Viral Vector Production
- 16.4.3. Cell Sorting & Purification
- 16.4.4. Gene Editing
- 16.4.5. Others
16.5. Market Value Forecast, by Indication, 2017-2031
- 16.5.1. Oncology Disease
- 16.5.2. Cardiovascular Disease
- 16.5.3. Orthopedic Disease
- 16.5.4. Infectious Disease
- 16.5.5. Others
16.6. Market Value Forecast, by End-user, 2017-2031
- 16.6.1. Pharmaceutical & Biotechnology Companies
- 16.6.2. Contract Manufacturing Organizations (CMOs)
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
- 16.8.1. By Therapy Type
- 16.8.2. By Product Type
- 16.8.3. By Technology
- 16.8.4. By Indication
- 16.8.5. By End-user
- 16.8.6. By Country/Sub-region

17. Competition Landscape

17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
- 17.3.1. Becton, Dickinson and Company
  - 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.1.2. Product Portfolio
  - 17.3.1.3. Financial Overview
  - 17.3.1.4. SWOT Analysis
  - 17.3.1.5. Strategic Overview
- 17.3.2. Bio-Rad Laboratories, Inc.
  - 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.2.2. Product Portfolio
  - 17.3.2.3. Financial Overview
  - 17.3.2.4. SWOT Analysis
  - 17.3.2.5. Strategic Overview
- 17.3.3. Bio-Techne Corporation
  - 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.3.2. Product Portfolio
  - 17.3.3.3. Financial Overview
  - 17.3.3.4. SWOT Analysis
  - 17.3.3.5. Strategic Overview
- 17.3.4. Danaher Corporation
  - 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.4.2. Product Portfolio
  - 17.3.4.3. Financial Overview
  - 17.3.4.4. SWOT Analysis
  - 17.3.4.5. Strategic Overview
- 17.3.5. General Electric Company (GE Healthcare)
  - 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.5.2. Product Portfolio
  - 17.3.5.3. Financial Overview
  - 17.3.5.4. SWOT Analysis
  - 17.3.5.5. Strategic Overview
- 17.3.6. Getinge AB
  - 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.6.2. Product Portfolio
  - 17.3.6.3. Financial Overview
  - 17.3.6.4. SWOT Analysis
  - 17.3.6.5. Strategic Overview
- 17.3.7. Lonza Group Ltd.
  - 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.7.2. Product Portfolio
  - 17.3.7.3. Financial Overview
  - 17.3.7.4. SWOT Analysis
  - 17.3.7.5. Strategic Overview
- 17.3.8. Merck KGaA
  - 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.8.2. Product Portfolio
  - 17.3.8.3. Financial Overview
  - 17.3.8.4. SWOT Analysis
  - 17.3.8.5. Strategic Overview
- 17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
  - 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.9.2. Product Portfolio
  - 17.3.9.3. Financial Overview
  - 17.3.9.4. SWOT Analysis
  - 17.3.9.5. Strategic Overview
- 17.3.10. Thermo Fisher Scientific Inc.
  - 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.10.2. Product Portfolio
  - 17.3.10.3. Financial Overview
  - 17.3.10.4. SWOT Analysis
  - 17.3.10.5. Strategic Overview
- 17.3.11. MaxCyte
  - 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.11.2. Product Portfolio
  - 17.3.11.3. Financial Overview
  - 17.3.11.4. SWOT Analysis
  - 17.3.11.5. Strategic Overview
- 17.3.12. Fresenius Medical Care AG & Co. KGaA
  - 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 17.3.12.2. Product Portfolio
  - 17.3.12.3. Financial Overview
  - 17.3.12.4. SWOT Analysis
  - 17.3.12.5. Strategic Overview

細胞および遺伝子治療製造市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Cell and Gene Therapy Manufacturing Market (Therapy Type: Cell Therapy and Gene Therapy; Product Type: Consumables, Equipment, and Software) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

細胞および遺伝子治療製造市場- レポートの範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：細胞および遺伝子治療製造市場

第4章 市場概要

第5章 主要な洞察

第6章 細胞および遺伝子治療製造市場の分析と予測：治療法別

第7章 細胞および遺伝子治療製造市場の分析と予測：製品タイプ別

第8章 細胞および遺伝子治療製造市場の分析と予測：テクノロジー別

第9章 細胞および遺伝子治療製造市場の分析と予測：適応症別

第10章 細胞および遺伝子治療製造市場の分析と予測：エンドユーザー別

第11章 細胞および遺伝子治療製造市場の分析と予測：地域別

第12章 北米の細胞および遺伝子治療製造市場の分析と予測

第13章 欧州の細胞および遺伝子治療製造市場の分析と予測

第14章 アジア太平洋の細胞および遺伝子治療製造市場の分析と予測

第15章 ラテンアメリカの細胞および遺伝子治療製造市場の分析と予測

第16章 中東およびアフリカの細胞および遺伝子治療製造市場の分析と予測

第17章 競合情勢